Macrophages and islet inflammation in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 152-158

  Eguchi, K ^a   Manabe, I ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Diabetes; Fatty acid; Inflammation; Innate immunity; Macrophage

Indexed keywords

ADIPOCYTOKINE; GLUCOSE; INFLAMMASOME; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; CELL FUNCTION; CELL POLARITY; HUMAN; INSULIN RESISTANCE; MACROPHAGE; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PROTEIN EXPRESSION; REVIEW;

DIABETES; FATTY ACID; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE;

ANIMALS; CELL POLARITY; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MACROPHAGES;

EID: 84883530920     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12168     Document Type: Review

References (63)

1. Couzin-Frankel J. Inflammation bares a dark side. Science 2010; 330: 1621.
2. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739-2748.
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
4. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010; 15: 543-562.
5. Kumar V, Abbas AK, Aster JC, Fausto N. Acute and chronic inflammation. In: Robbins and Cotran Pathologic Basis of Disease. Philadelphia: Saunders, 2009; 43-77.
6. Calay ES, Hotamisligil GS. Turning off the inflammatory, but not the metabolic, flames. Nat Med 2013; 19: 265-267.
7. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
8. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
9. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14: 222-231.
10. Westermark P. Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 1972; 77: 91-94.
11. Ehses JA, Perren A, Eppler E et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356-2370.
12. Yoon KH, Ko SH, Cho JH et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
13. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
14. Boni-Schnetzler M, Boller S, Debray S et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-5229.
15. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50: 77-82.
16. Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem 2000; 275: 36509-36513.
17. Heimberg H, Heremans Y, Jobin C et al. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. Diabetes 2001; 50: 2219-2224.
18. Oyadomari S, Araki E, Mori M. Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 2002; 7: 335-345.
19. Karlsen AE, Ronn SG, Lindberg K et al. Suppressor of cytokine signaling 3 (SOCS-3) protects beta-cells against interleukin-1beta - and interferon-gamma -mediated toxicity. Proc Natl Acad Sci USA 2001; 98: 12191-12196.
20. Flodstrom M, Eizirik DL. Interferon-gamma-induced interferon regulatory factor-1 (IRF-1) expression in rodent and human islet cells precedes nitric oxide production. Endocrinology 1997; 138: 2747-2753.
21. El Muayed M, Billings LK, Raja MR et al. Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function. J Endocrinol 2010; 206: 159-169.
22. Maedler K, Schumann DM, Sauter N et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006; 55: 2713-2722.
23. Stassi G, Maria RD, Trucco G et al. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186: 1193-1200.
24. Schumann DM, Maedler K, Franklin I et al. The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci USA 2007; 104: 2861-2866.
25. Suarez-Pinzon W, Sorensen O, Bleackley RC, Elliott JF, Rajotte RV, Rabinovitch A. Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. Diabetes 1999; 48: 21-28.
26. Eizirik DL, Sandler S, Welsh N, Juntti-Berggren L, Berggren PO. Interleukin-1 beta-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation. Mol Cell Endocrinol 1995; 111: 159-165.
27. Ellingsgaard H, Hauselmann I, Schuler B et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17: 1481-1489.
28. Bending D, Zaccone P, Cooke A. Inflammation and type one diabetes. Int Immunol 2012; 24: 339-346.
29. Hume DA, Halpin D, Charlton S, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Macrophages of endocrine organs. Proc Natl Acad Sci USA 1984; 81: 4174-4177.
30. Banaei-Bouchareb L, Gouon-Evans V, Samara-Boustani D et al. Insulin cell mass is altered in CSF1op/CSF1op macrophage-deficient mice. J Leukoc Biol 2004; 76: 359-367.
31. Banaei-Bouchareb L, Peuchmaur M, Czernichow P, Polak M. A transient microenvironment loaded mainly with macrophages in the early developing human pancreas. J Endocrinol 2006; 188: 467-480.
32. Tessem JS, Jensen JN, Pelli H et al. Critical roles for macrophages in islet angiogenesis and maintenance during pancreatic degeneration. Diabetes 2008; 57: 1605-1617.
33. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
34. Mantovani A. Macrophage diversity and polarization: in vivo veritas. Blood 2006; 108: 408-409.
35. Eguchi K, Manabe I, Oishi-Tanaka Y et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab 2012; 15: 518-533.
36. Masters SL, Dunne A, Subramanian SL et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
37. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
38. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
39. Charles MA, Eschwege E, Thibult N et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. Diabetologia 1997; 40: 1101-1106.
40. Riserus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 2009; 48: 44-51.
41. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70: 1560-1566.
42. Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of type 2 diabetes. Biochem Soc Trans 2008; 36: 348-352.
43. Chang-Chen K, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008; 9: 329-343.
44. Fonseca SG, Gromada J, Urano F. Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol Metab 2011; 22: 266-274.
45. Klein I, Cornejo JC, Polakos NK et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 2007; 110: 4077-4085.
46. Ginhoux F, Greter M, Leboeuf M et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330: 841-845.
47. Merad M, Manz MG, Karsunky H et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002; 3: 1135-1141.
48. Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res 1999; 117: 145-152.
49. Schulz C, Perdiguero EG, Chorro L et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336: 86-90.
50. Hess D, Li L, Martin M et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003; 21: 763-770.
51. Lin SL, Castano AP, Nowlin BT, Lupher ML Jr, Duffield JS. Bone marrow Ly6chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009; 183: 6733-6743.
52. Fujiu K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011; 121: 3425-3441.
53. Mildner A, Schmidt H, Nitsche M et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007; 10: 1544-1553.
54. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
55. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
56. Ehses JA, Lacraz G, Giroix MH et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 2009; 106: 13998-14003.
57. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008; 149: 2208-2218.
58. van Asseldonk EJP, Stienstra R, Koenen TB, Joosten LAB, Netea MG, Tack CJ. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011; 96: 2119-2126.
59. Cavelti-Weder C, Babians-Brunner A, Keller C et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662.
60. Dominguez H, Storgaard H, Rask-Madsen C et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-525.
61. Gupta-Ganguli M, Cox K, Means B, Gerling I, Solomon SS. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care 2011; 34: e121.
62. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007; 36: 91-96.
63. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152: 346-357.